StockData
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. (AUPH) company profile

AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3059% below fair value
$15.40−0.08 (-0.52%)

Close on Nov 17, 2026Market cap $2.06BP/E 6.7Yield –

About Aurinia Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Aurinia is a biopharmaceutical company that develops and commercializes medical therapies for individuals affected by autoimmune conditions. The company's principal commercial product is voclosporin, branded as Lupkynis, an oral calcineurin inhibitor prescribed for adult patients suffering from active lupus nephritis. Additionally, the company is developing aritinercept, an investigational dual inhibitor targeting cytokines that regulate B-cell activity for autoimmune disorders. In the United States, Aurinia supplies Lupkynis directly to a specialty distributor alongside two specialty pharmacies. For international markets, it provides commercial inventory to its collaboration partner, Otsuka Pharmaceutical, which handles distribution across Europe and Japan.

The organization maintains a workforce of 128 full-time equivalent employees and utilizes external contract manufacturers for drug substance production, capsule encapsulation, and product packaging. Lupkynis holds regulatory approvals and commercial distribution across the United States, Japan, Switzerland, the United Kingdom, and the European Union, with licensing rights extending to additional territories including Norway, Iceland, and Ukraine. The text does not disclose the location of the company's corporate headquarters.

Summary of the business section of Aurinia Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Aurinia Pharmaceuticals Inc.
Headquarters
Edmonton, A0
Address
#140, 14315 - 118 Avenue T5L 4S6
Phone
(250) 744-2487
Employees
128, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Edmonton, Canada

Stock & identifiers

Ticker
AUPH
Exchange
Nasdaq
IPO date
Sep 3, 2014
Shares outstanding
134M, Oct 29, 2026
Public float
$1.00B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1600620
CUSIP
05156V102
ISIN
US05156V1026
FIGI
BBG000BCRJM5
Share class FIGI
BBG001S68013
LEI
5299008YP2BW4570ML28
EIN
98-1231763

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Kevin TangChief Executive Officer, Director13,044,106
Peter GreenleafChief Executive Officer, Director1,840,379
Stephen P. RobertsonChief Legal Officer576,981
Ryan ColeChief Operating Officer116,144
Michael S. HearneChief Financial Officer116,144
Greg KeenanSVP, Chief Medical Officer154,449
Joseph M. MillerChief Financial Officer576,421
Matthew Maxwell DonleyChief Operating Officer680,299
Kathleen GoetzDirector–
Craig A. JohnsonDirector14,592
Jeffrey Allen BaileyDirector22,775
Tina Susan NovaDirector–
Karen L. SmithDirector24,807
David R.W. JayneDirector56,499
Jill LeversageDirector26,453

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$5.86M$17.55M$2.06M$115$84
FY2024$6.42M$7.62M$2.21M$65$63
FY2023$10.57M$14.92M$3.89M$65$69
FY2022$8.84M-$8.90M$3.28M$31$70
FY2021$1.24M$16.34M$718.16K$165$92
FY2020$10.68M-$2.60M$3.23M$68$129

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Peter Greenleaf
Former Chief Executive Officer
$822.88K$1.97M$2.19M$864.02K$13.18K$5.86M-9%
Joseph Miller
Former Chief Financial Officer
$526.99K$550.65K$614.49K$395.24K$15.38K$2.10M-8%
Matthew Donley
Former Chief Operating Officer
$567.64K$559.60K$624.48K$425.73K$59.64K$2.24M-11%
Gregory Keenan, M.D.
Former Chief Medical Officer
$516.23K$423.06K$472.11K$348.46K$14.38K$1.77M+34%
Stephen Robertson
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
$481.90K$568.56K$634.47K$361.43K$80.16K$2.13M-4%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of February 25, 2026, we had 128 full-time equivalent employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?